Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next Generation Sequencing Facilitates Quantitative Analysis of Mycobacterium smegmatis C2 155 Transcriptomes treated with rifampicin and glutamine

ABSTRACT: Next Generation Sequencing Facilitates Quantitative Analysis of Mycobacterium smegmatis C2 155 Transcriptomes treated with rifampicin and glutamine

PROVIDER: PRJNA422199 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Next Generation Sequencing Facilitates Quantitative Analysis of Mycobacterium smegmatis C2 155 Transcriptomes treated with rifampicin and glutamine

Project description:We report the application of single-molecule-based sequencing technology for high-throughput profiling of histone modifications in mycobacterium smegmatis C2 155. By obtaining over four billion bases of sequence from chromatin immunoprecipitated DNA, we generated genome-wide chromatin-state maps of Mycobacterium smegmatis C2 155. We find that amino acids synthesis and degradation genes, genes that are expressed.The ratio of gene expression based on transcriptome substantiate an enhanced TCA cycle. The upregulation of Lys1 was found to prompt this degradation of lysine. The transformation from glutamine to glutamate as well as arginine was mediated by glsA (MSMEG_3818) , of which glutamate engaged into the TCA cycle via α-ketoglutarate. The phenylalanine was degraded into fumarate via mhpB. The succinate formation from asparate degradation was mediated by methylcitrate dehydratase (MSMEG_6645), carboxyvinyl-carboxyphosphonate phosphorylmutase (MSMEG_2506) and MSMEG_6855. and therefore reflect metabolism state of strains. Data from sample treated with rifampicin/glutamine reveals the upregulation of respiration.

2018-12-21 | GSE108001 | GEO

Proteomic Time-Course Investigation into the Effects of Exposure of Mycobacterium smegmatis to Sub-Lethal Dose of Rifampicin

Project description:Drug susceptible Mycobacterium smegmatis (Mc2-155) was exposed to a sub-MIC concentration of antimycobacterial drug Rifampicin (treated) or DMSO (control). Cells were harvested at 30, 255 and 300 minutes post-exposure and the proteome at each time analysed using LC-MS/MS on a Thermo Q-Exactive.

2017-03-15 | PXD004197 | Pride

Proteomic Time-Course Investigation into the Effects of Exposure of Mycobacterium smegmatis to Sub-Lethal Dose of Rifampicin

2019-03-18 | MSV000083589 | MassIVE

Mycolicibacterium smegmatis MC2 155

Project description:Mycolicibacterium smegmatis MC2 155 Raw sequence reads

| PRJNA518044 | ENA

Mycolicibacterium smegmatis MC2 155

Project description:Mycolicibacterium smegmatis MC2 155 Raw sequence reads

| PRJNA320082 | ENA

Mycolicibacterium smegmatis MC2 155

Project description:Mycolicibacterium smegmatis MC2 155 Raw sequence reads

| PRJNA382823 | ENA